×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
INCY – incyte corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
INCY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/4
07:44 am
incy
Trevi Therapeutics appoints new CFO [Seeking Alpha]
Low
Report
Trevi Therapeutics appoints new CFO [Seeking Alpha]
12/3
04:30 pm
incy
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/3
03:16 pm
incy
Incyte Corporation (INCY) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Incyte Corporation (INCY) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
12/2
09:15 am
incy
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
Low
Report
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
12/1
08:00 am
incy
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
Low
Report
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
11/27
07:07 pm
incy
Incyte (INCY) Up 17.2% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
Low
Report
Incyte (INCY) Up 17.2% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
11/27
04:11 am
incy
Incyte: This Profitable Biotech Trades Like A Melting Iceberg [Seeking Alpha]
Low
Report
Incyte: This Profitable Biotech Trades Like A Melting Iceberg [Seeking Alpha]
11/27
01:12 am
incy
Incyte: Riding Jakafi, Bracing For Generic Headwinds [Seeking Alpha]
Low
Report
Incyte: Riding Jakafi, Bracing For Generic Headwinds [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/3
04:37 pm
incy
Form 4 INCYTE CORP For: Dec 01 Filed by: Stein Steven H
Low
Report
Form 4 INCYTE CORP For: Dec 01 Filed by: Stein Steven H
12/3
04:36 pm
incy
Form 4 INCYTE CORP For: Dec 01 Filed by: Morrissey Michael James
Low
Report
Form 4 INCYTE CORP For: Dec 01 Filed by: Morrissey Michael James
12/3
04:36 pm
incy
Form 4 INCYTE CORP For: Dec 01 Filed by: Hoffman Richard A.
Low
Report
Form 4 INCYTE CORP For: Dec 01 Filed by: Hoffman Richard A.
12/3
04:34 pm
incy
Form 3 INCYTE CORP For: Dec 01 Filed by: Hoffman Richard A.
Low
Report
Form 3 INCYTE CORP For: Dec 01 Filed by: Hoffman Richard A.
12/2
04:05 pm
incy
Form 144 INCYTE CORP Filed by: Stein Steven H
Low
Report
Form 144 INCYTE CORP Filed by: Stein Steven H
12/1
04:05 pm
incy
Form 144 INCYTE CORP Filed by: Stein Steven H
Low
Report
Form 144 INCYTE CORP Filed by: Stein Steven H
11/25
04:02 pm
incy
Form 4 INCYTE CORP For: Nov 21 Filed by: Tray Thomas
Low
Report
Form 4 INCYTE CORP For: Nov 21 Filed by: Tray Thomas
11/24
04:14 pm
incy
Form 144 INCYTE CORP Filed by: Tray Thomas
Low
Report
Form 144 INCYTE CORP Filed by: Tray Thomas
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/5
Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium
7.1%
7/30 Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs 6.4%
3/13 Incyte Co. (NASDAQ: INCY) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. They now have a $83.00 price target on the stock. 6.4%
3/26 Incyte Names New Member to Its Board of Directors 5.9%
1/13 Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.7%
11/25 Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting 5.3%
4/15 Form 4 INCYTE CORP For: Apr 13 Filed by: Pasquale Maria E 5.2%
2/18 Form 4 INCYTE CORP For: Feb 13 Filed by: Pasquale Maria E 4.0%
9/19 Form 4 INCYTE CORP For: Sep 18 Filed by: SWAIN PAULA J 4.0%
3/24 Blair likes Incyte in premarket analyst action [Seeking Alpha] 3.5%
7/30 Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs 6.4%
3/13 Incyte Co. (NASDAQ: INCY) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. They now have a $83.00 price target on the stock. 6.4%
3/26 Incyte Names New Member to Its Board of Directors 5.9%
1/13 Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.7%
11/25 Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting 5.3%
4/15 Form 4 INCYTE CORP For: Apr 13 Filed by: Pasquale Maria E 5.2%
2/18 Form 4 INCYTE CORP For: Feb 13 Filed by: Pasquale Maria E 4.0%
9/19 Form 4 INCYTE CORP For: Sep 18 Filed by: SWAIN PAULA J 4.0%
3/24 Blair likes Incyte in premarket analyst action [Seeking Alpha] 3.5%
TOP News Decliners
1/2
Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease
-9.4%
5/10 Form 4 INCYTE CORP For: May 09 Filed by: Iyengar Vijay K -6.1%
3/26 Form 8-K INCYTE CORP For: Mar 25 -5.6%
6/7 Form SC 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP -5.0%
9/23 Incyte to Host Investor Conference Call from ESMO 2019 -4.6%
1/28 Incyte's skin disease drug meets main goal in late-stage study [Reuters] -3.8%
3/10 Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating [Investor's Business Daily] -3.2%
9/27 Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma -3.2%
9/12 Incyte Co. (NASDAQ: INCY) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating on the stock. -3.1%
8/27 BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 -3.1%
5/10 Form 4 INCYTE CORP For: May 09 Filed by: Iyengar Vijay K -6.1%
3/26 Form 8-K INCYTE CORP For: Mar 25 -5.6%
6/7 Form SC 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP -5.0%
9/23 Incyte to Host Investor Conference Call from ESMO 2019 -4.6%
1/28 Incyte's skin disease drug meets main goal in late-stage study [Reuters] -3.8%
3/10 Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating [Investor's Business Daily] -3.2%
9/27 Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma -3.2%
9/12 Incyte Co. (NASDAQ: INCY) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating on the stock. -3.1%
8/27 BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: